Skip to main content

Table 6 Intensities of the peaks for different categories of hormone-receptor status, Her2/neu and P53 expression and menopause status

From: Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study

   M/z4276 M/z4292 M/z8129 M/z8941
  n Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
Median intensity
(IQR)
ER status      
   Negative 12 15.2
(0.7–70.6)
18.3
(6.2–48.1)
26.3
(25.2–28.5)
39.9
(24.3–57.5)
   Positive 35 11.0
(3.9–24.3)
14.5
(8.9–22.9)
25.7
(17.9–28.2)
30.5
(24.1–43.4)
p-value* 47 .961 .696 .421 .380
PR status      
   Negative 19 7.1
(4.0–29.3)
10.9
(8.5–30.8)
26.0
(21.7–27.8)
31.3
(24.0–43.3)
   Positive 28 14.6
(1.8–28.2)
15.4
(6.8–28.7)
25.8
(19.5–29.6)
32.1
(24.1–46.7)
p-value* 47 .649 .696 .762 .588
Her2/neu expression      
   Negative 35 11.0
(1.9–29.3)
15.9
(5.6–29.5)
25.9
(20.5–27.8)
32.9
(24.1–46.9)
   Positive 12 9.5
(4.3–66.2)
11.1
(9.1–43.2)
26.0
(16.2–29.3)
29.7
(23.3–41.7)
p-value* 47 .961 .826 .751 .575
P53 expression      
   Negative 18 6.5
(1.6–24.3)
12.7
(5.3–31.3)
23.7
(17.6–26.8)
27.1
(17.7–42.6)
   Positive 23 11.0
(4.7–29.4)
14.9
(8.9–29.5)
26.5
(24.8–30.1)
32.9
(27.8–60.8)
p-value* 41 .599 .546 .070 .172
Menopause status      
   Premenopausal 15 7.9
(1.9– 84.3)
12.2
(10.1–69.2)
27.6
(22.2–32.7)
29.0
(22.7–43.3)
   Postmenopausal 30 10.2
(2.0–25.6)
14.3
(5.5–29.8)
25.3
(17.8–26.6)
32.1
(24.2–45.4)
p-value* 45 .942 .580 .030 .563
  1. M/z = Mass to Charge ratio, IQR = Inter-Quartile Range, * Mann-Whitney U Test, ER = Oestrogen Receptor, PR = Progesterone Receptor